novartis-$400m hep c deal, page-4

I'm no RGC,

However like the article suggests it will be part of a cocktail treatment. EDP-239 is just a NS5A inhibitor . NS5A inhibitors target small molecules of the HCV NS5A protein, wich plays a part in the virion production, with could lead to antiviral resistance. The idea is that it will help with suppression of virus replication- So again like the article suggests the idea would be to run cocktail trails with protease, and polymerase inhibitors on treatment naive patients or poor responders to SOC. IMO NS5A inhibitors, and Biotron's P7 inhibitor( BIT225) could play a Similar role in an HCV cocktail.

Note: The big dogs already have NS5A inhibiotrs in their line ups, however rumored take over targets like ACHN have run promising cocktail trails with NS5A inhiblitor's. Watch their SP over night...It always moves on news.